Alnylam Pharmaceuticals Shares Are Trading Lower. The Company Announced Results From Its HELIOS-B Phase 3 Study of Vutrisiran, an Investigational RNAi Therapeutic in Development for the Treatment of ATTR Amyloidosis With Cardiomyopathy.
Alnylam Pharmaceuticals Shares Are Trading Lower. The Company Announced Results From Its HELIOS-B Phase 3 Study of Vutrisiran, an Investigational RNAi Therapeutic in Development for the Treatment of ATTR Amyloidosis With Cardiomyopathy.
阿里拉姆製藥股價下跌。該公司宣佈了其HELIOS-b第3期研究藥物Vutrisiran的結果，該藥物是一種用於治療具有心肌病的ATTR澱粉樣變性的RNAi療法。
Alnylam Pharmaceuticals Shares Are Trading Lower. The Company Announced Results From Its HELIOS-B Phase 3 Study of Vutrisiran, an Investigational RNAi Therapeutic in Development for the Treatment of ATTR Amyloidosis With Cardiomyopathy.
Alnylam製藥公司股價走低。該公司公佈了其對Vutrisiran的Helios-B三期研究結果，Vutrisiran是一種正在開發的用於治療心肌病ATTR澱粉樣變的研究性RNAi療法。